Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK inhibitors from past to present: A new wave of cancer therapy
Muhammad Jameel, Kinjal Bhadresha, Hang Fai Kwok
Seminars in Cancer Biology (2022) Vol. 88, pp. 106-122
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 141
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Cynthia L. Palmer, Britton Boras, Bernadette Pascual, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 464-481.e14
Open Access | Times Cited: 3
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 14
CDK Inhibitors and FDA: Approved and Orphan
Jonas Cicenas, Jokubas Simkus
Cancers (2024) Vol. 16, Iss. 8, pp. 1555-1555
Open Access | Times Cited: 9
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors
Jiangmin Zhu, Yuxing Cai, Min Kong, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2758-2776
Closed Access | Times Cited: 6
Role of Cyclins and Cytoskeletal Proteins in Endometriosis: Insights into Pathophysiology
Marcin Szymański, Klaudia Bonowicz, Paulina Antosik, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 836-836
Open Access | Times Cited: 6
CIP/KIP and INK4 families as hostages of oncogenic signaling
Lucia Csergeová, David Krbušek, Radoslav Janoštiak
Cell Division (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 6
CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review
D. Pavlović, Danijela Niciforovic, Dragana Papic, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 15
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, et al.
Wiley Interdisciplinary Reviews - RNA (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Pyrrolo[2,3-d]pyrimidines as potential kinase inhibitors in cancer drug discovery: A critical review
Malyala Sai Madhurya, Vanashree Thakur, Sowmya Dastari, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107867-107867
Closed Access | Times Cited: 5
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
Qingyi Hu, Tao Huang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8939-8939
Open Access | Times Cited: 12
The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis
Jinquan Zhao, Zhou Qiqi, Yuan Sun, et al.
Phytomedicine (2024) Vol. 130, pp. 155734-155734
Closed Access | Times Cited: 4
Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review
Ziqiang Liu, Qian Zhang, Yulin Liu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117847-117847
Closed Access | Times Cited: 4
Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
Bei Zhang, Yanhong Li, Yukang Lin, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Local Control of Advanced Breast Cancer—Debate in Multidisciplinary Tumor Board
Iuliana Pantelimon, Andra Maria Stancu, Simona Coniac, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 510-510
Open Access
Microfluidic fabrication of lipid nanoparticles for co-delivery of siRNA and hydroxychloroquine: An engineered theranostic platform for enhanced breast cancer treatment
Lu Huang, Wenli Guo, Ting Zhao, et al.
Chemical Engineering Journal (2025), pp. 160172-160172
Open Access
Harnessing p53 for targeted cancer therapy: new advances and future directions
Zdeněk Andrysík, Joaquı́n M. Espinosa
Transcription (2025), pp. 1-44
Open Access
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
Jeanine Giarolla, Kelsey Holdaway, Maryam Nazari, et al.
Future Medicinal Chemistry (2025), pp. 1-21
Closed Access
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
European Journal of Medicinal Chemistry (2025) Vol. 290, pp. 117503-117503
Closed Access
Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells
Ermira Mulliqi, Said Khelwatty, Anna Morgan, et al.
World Journal of Oncology (2024) Vol. 15, Iss. 3, pp. 492-505
Open Access | Times Cited: 3
Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment
Rahul Dubey, Rahul Makhija, Anushka Sharma, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107508-107508
Closed Access | Times Cited: 3
Inhibitors and PROTACs of CDK2: challenges and opportunities
Yangjie Zeng, Xiaodong Ren, Pengyao Jin, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1125-1148
Closed Access | Times Cited: 3
Integrating Molecular Dynamics and Machine Learning Algorithms to Predict the Functional Profile of Kinase Ligands
Elena Frasnetti, Ivan Cucchi, Silvia Pavoni, et al.
Journal of Chemical Theory and Computation (2024) Vol. 20, Iss. 20, pp. 9209-9229
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top